REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-18. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Northern Ireland Patrick John Allen, Detective Sergeant, Royal Ulster Constabulary. Trevor William Campbell, Detective Inspector, Royal Ulster Constabulary. William Joseph Coalter, Sergeant, Royal Ulster Constabulary. Overseas Keith Braithwaite, Chief Superintendent, Royal Hong Kong Police. Christopher John Glover, Chief Superintendent, Royal Hong Kong Police. Lau Chun-sing, Chief Superintendent, Royal Hong Kong Police. William Ian Nicholson, Chief Superintendent, Royal Hong Kong Police.
=== Development === Scandal was renewed for a fifth season on May 7, 2015, by ABC. The series will continue to air at Thursdays in the timeslot 9:00 p.m. E.T. like the previous season, as it was moved to the timeslot to make room for ShondaLand Production Company's new TV series, How to Get Away with Murder. Production began on May 21, 2015, when Rhimes announced on Twitter that the writers were in full swing mapping the fifth season. The remaining fall schedule for ABC was announced on November 16, 2015, where it was announced that Scandal would air nine episodes in the fall with the fall finale to air on November 19, 2015, just like the rest of ABC's primetime lineup "TGIT" Grey's Anatomy and How To Get Away with Murder, which was the same last year. The remaining 12 episodes will air after the winter break, beginning on February 11, 2016, as a result of ABC airing the television miniseries Madoff over two nights on February 3–4, 2016 in the same time-slot as Scandal and Grey's Anatomy. The show was renewed by ABC for a sixth season on March 3, 2016.
March 31, 2004: The Ministry Delegate for Parity and Professional Equality gains its autonomy. May 26, 2004: Law concerning divorce; the protection of the spouse victim of violence is taken into account. July 1, 2004: Decree concerning the conditions for performing voluntary terminations of pregnancy outside healthcare establishments and amending the Public Health Code (second part: Regulatory part). August 6, 2004: Law concerning bioethics. November 24, 2004: Plan to combat violence against women. November 24, 2004: Ordinance concerning the legislative part of the Code on the Entry and Residence of Foreigners and the Right of Asylum. March 23, 2006: Law concerning equal pay between women and men. April 5, 2006: Law on strengthening the prevention and repression of violence within couples or against minors. December 30, 2004: Law establishing the French Equal Opportunities and Anti-Discrimination Commission (HALDE). March 17, 2005: Decree concerning the family reunification of foreigners for the application of Book IV of the Code on the Entry and Residence of Foreigners and the Right of Asylum. April 2, 2005: Orientation and Program Law for the Future of the School, which emphasizes that it must "promote coeducation and equality between men and women." June 2, 2005: Creation of the Ministry Delegate for Social Cohesion and Parity. July 4, 2005: Ordinance reforming filiation. August 2, 2005: Law in favor of small and medium-sized enterprises; it notably includes provisions concerning the status of the collaborating spouse.
Sources: en.wikipedia.org
On 16 February, the Syrian government forces intensified their drone attacks, which resulted in the death of one person and five injuries in the Mansoura-Walgha village area. A car exploded in Al-Qurayya, injuring two people, a Syrian source stated that the car was carrying weapons and ammunition. On 17 February, the emir of Dar Ara, Abu Yahya Hassan Al-Atrash, defected to the Syrian government forces, arriving at Daraa Governorate from Suwayda, sources stated that Hikmat al-Hijri does not want other leaders in Suwayda, except him. On 19 February, an unknown group kidnapped Yahya al-Hajjar, the former leader of Men of Dignity, on his farm in rural Suwayda, the Men of Dignity declared a state of maximum alert immediately after the kidnapping, when al-Hajjar was released, he was taken to the guesthouse of the Men of Dignity leader, Sheikh Mazid Khaddaj. On 22 February, the Syrian government forces launched attacks toward Al-Majdal, the National Guard responded to the attacks. On 24 February, an armed group from the village of Labin attacked the Internal Security Forces after an attempt to free one of its members who had been arrested for theft. At the Suwayda headquarters of the Criminal Security branch, the Rapid Intervention Battalion, led by Ruad Abdul Khaliq, clashed with a group from the Abu Sarhan family.
=== Laboratory testing === Because newborn screening programs test for a number of conditions, a number of laboratorial methodologies are used, as well as bedside testing for hearing loss using evoked auditory potentials and congenital heart defects using pulse oximetry. In the early 1960s Newborn screening started out using simple bacterial inhibition assays to screen for a single disorder, starting with phenylketonuria. With this testing methodology, newborn screening required one test to detect one condition. As mass spectrometry became more widely available, the technology allowed rapid determination of a number of acylcarnitines and amino acids from a single dried blood spot. This increased the number of conditions that could be detected by newborn screening. Enzyme assays are used to screen for galactosemia and biotinidase deficiency. Immunoassays measure thyroid hormones for the diagnosis of congenital hypothyroidism and 17α-hydroxyprogesterone for the diagnosis of congenital adrenal hyperplasia. Molecular techniques are used for the diagnosis of cystic fibrosis and severe combined immunodeficiency. As of 2023, numerous initiatives using next generation sequencing (NGS) have been announced worldwide including the Genomic Uniform-screening Against Rare Diseases in All Newborns (GUARDIAN study), BeginNGS and Early Check in the USA, BabyScreen+ in Australia, Generation Study by Genomics England, and Screen4Care, Baby Detect in Belgium and PERIGENOMED in France.
=== Vaccine Impact Modelling Consortium === The Vaccine Impact Modelling Consortium (VMIC) consists of mathematical models of diseases to analyze the impact of Gavi's vaccines, mainly in terms of deaths averted and disability-adjusted life year loss prevented, and to help Gavi come up with ways to maximize the impact for a given amount of resources. It consists of several different groups of modellers working independently. In 2026, the VMIC published an analysis on the impact Gavi's vaccination programmes against 14 vaccine-preventable diseases across 117 low- and middle-income families. In terms of lives saved per 1000 vaccinations, HPV (11.24), measles (6.09), HepB (5.00), and malaria (2.78) were found to be the most imapctful. In terms of DALY-loss prevented per 1000 vaccinations, HPV (523.04), measles (411.01), malaria (203.04), and Hib (150.37) were the most impactful. This analysis describes the effect of increasing vaccination on top of an existing level of coverage and disease burden, so vaccinating against a disease that has already achieved herd immunity can appear less impactful.
The original protein and sequence are highly conserved in evolution, and are found in humans, chimpanzees, rhesus monkeys, and bush babies. Addison's disease (typically an autoimmune destruction of the adrenal glands) may also be seen in individuals with vitiligo.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.